Short Interest in UCB SA (OTCMKTS:UCBJF) Drops By 63.1%

UCB SA (OTCMKTS:UCBJF - Get Free Report) saw a significant decrease in short interest in April. As of April 15th, there was short interest totalling 215,500 shares, a decrease of 63.1% from the March 31st total of 584,000 shares. Based on an average daily volume of 200 shares, the short-interest ratio is presently 1,077.5 days. Approximately 0.1% of the company's shares are sold short.

UCB Price Performance

Shares of OTCMKTS UCBJF remained flat at $150.70 during trading on Wednesday. The company has a quick ratio of 0.78, a current ratio of 1.19 and a debt-to-equity ratio of 0.33. UCB has a fifty-two week low of $126.05 and a fifty-two week high of $209.66. The stock has a 50-day simple moving average of $175.50 and a 200-day simple moving average of $182.81.

About UCB

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.